Conference Day One

8:25 am Chair’s Opening Remarks

In-Human Studies to Boost Confidence in Inflammasome Therapeutic Clinical Trials & Progressing Forward With Therapeutic Candidates for Specific Diseases

8:30 am Preclinical to Clinical Development: Targeting the NLRP3 Inflammasome in Myelodysplastic Syndrome


  • NLRP3 inflammasome is constitutively active in myelodysplastic syndrome (MDS)
  • Novartis is starting clinical trials to assess the impact of anti-inflammatory molecules in low-risk MDS

9:00 am A Comprehensive Approach to Investigating Inflammasome Function & Antagonism


  • Evaluating six putative NLRP3 inhibitors with the NanoBRET™ NLRP3 Target Engagement Assay, Caspase-Glo 1 Inflammasome Assay, and the Lumit™ IL-1β Immunoassays.
  • Developing the Lumit™ Immunoassay to specifically detect active IL-18.
  • Exploring the fundamentally different biology of IL-18 and IL-1β using Lumit™ and Caspase-Glo tools.

9:30 am Advancing NT-0796 to the Clinic for Central Nervous System Indications

  • Alan Watt Chief Executive Officer, NodThera Ltd.


  • Collating the preclinical data to support the indication decisions made prior to human studies
  • Reviewing the formulation and delivery decisions to achieve the optimal PK/PD profile
  • Navigating the next steps in the clinical development path in neurodegenerative diseases

10:00 am Speed Networking


Put a face to a name – this session is the perfect opportunity to get face-to-face time with the key opinion leaders in the inflammasome field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development in the autoimmune and inflammation field.

10:45 am Morning Break

Track One – Discovery Science & Mechanisms

Supercharging Inflammasome Targeting Therapeutics Beyond NLRP3 as Druggable Targets

11:00 am Frontier Inflammasome Therapeutics: Capitalizing on Inflammasome Structure to Function for Drugs Beyond NLRP3


  • Considerations of inflammasome assembly, regulation, and signalling to identify therapeutic targets
  • Assessing the opportunity mechanistically to develop new drug candidates beyond NLRP3 inhibitors

11:30 am Exploring the Opportunity of Therapeutically Targeting the Other NLRs: Understanding the Activators of NLRs in Disease Beyond Infections


  • Harnessing the knowledge of NLRP3 to understand whether NLRP1 will be activated similarly
  • Evaluating the druggability of inflammasomes beyond NLRP3

Track Two – Preclinical & Translational Advancements


Chair: Marianna Rowlands, Director, Immunology, Therapeutic Area Biomarker Lead, Translational Medicine, Novartis

Addressing the Biomarker Bottlenecks in Inflammasome Therapeutics R&D to Hone Effective Predictive Markers

11:00 am Implementing a Biomarker Strategy in Inflammasome Preclinical & In-Human Studies


  • Understanding the bench-to-bedside and back translation of biomarkers studied
  • Navigating biomarker selection for inflammasome therapeutics; the known and unknown

11:30 am Exploring Biomarkers: Early Clinical Evaluation of HT-6184 a Potent, Selective, Orally Bioavailable, Allosteric Inhibitor of Nek7/NLRP3


  • Discussing HT-6184 binds to Nek7, induces conformational rigidity that prevents Nek7 binding to NLRP3, and HT-6184 reverses NLRP3 inflammasome assembly
  • Analyzing biomarkers from secreted proteins from immune cells from patients from the phase 1 clinical trial and evaluating biomarkers for both patient selection and response evaluation

12:00 pm Lunch & Networking

Supercharging Inflammasome Targeting Therapeutics Beyond NLRP3 as Druggable Targets

1:00 pm Highlighting ASC Antibodies: Illuminating Disease Pathways Through Mechanistic Insights

  • Davide Basco Team Leader - Neuroinflammation, AC Immune SA


  • DMapping and development of functionally active monoclonal antibodies generated against different regions of ASC
  • Unveiling the mechanism of action of ASC antibodies to understand how antibody-mediated ASC inhibition can modify inflammatory processes
  • Discovering the potential therapeutic avenues in CNS and peripheral inflammatory diseases

1:30 pm Discovery of a first-in-class inflammasome pathway and multi-cytokine inhibitor for the treatment of Inflammatory Bowel Disease (IBD)


  • DESN-X is an oral, small-molecule gut-preferred, inflammasome assembly inhibitor discovered using optimization of a natural product lead discovered via phenotypic screening of inflammasome activation
  • ESN-X was discovered to be an allosteric modulator of HSP90 function via binding to its CTD, thereby modulating NLRP3 protein stability and inflammasome assembly
  • ESN-X, via a putative change in client protein interactions of HSP90, also potently inhibits TNFa and IL-23 signaling, which are validated targets for the treatment of IBD
  • The combination of limited systemic bioavailability and established preclinical safety suggests the opportunity for a novel approach to treating IBD. This approach holds promise as an orally administered multi-biologic, offering enhanced convenience and safety

Using & Implementing Biomarker Strategies to Step Towards Adopting & Validating Clinical Inflammasome Biomarkers

1:00 pm Panel Discussion: Uncovering the Tangible Translation of Biomarkers for Therapeutic Effectiveness & Target Engagement

  • Marianna Rowlands Director, Immunology Therapeutic Area Biomarker Lead, Translational Medicine, Novartis AG
  • David Bearss Chief Executive Officer, President & Chairman Of The Board, Halia Therapeutics
  • Harold Hoffman Professor & Chief of the Division of Allergy, Immunology and Rheumatology, University of California San Diego
  • Juan Pablo de Rivero Vaccari Associate Professor, University of Miami


  • Discussing the current state of play in inflammasome biomarkers to understand the landscape and missing pieces
  • Debating where to go next for inflammasome biomarker strategies and clinical development considerations

1:30 pm Roundtable Discussions: Inflammasome Biomarker Strategies


  • CNS vs peripheral inflammasome biomarkers
  • Peripheral biomarkers for CNS targeting therapeutics
  • Creating a preclinical and clinical biomarker strategy – where do we go?
  • Effectiveness of downstream biomarkers for inflammasome inhibitors/activators
  • Assessing PET probes for neuroinflammation biomarkers and inflammasome inhibitors

2:00 pm Afternoon Break & Poster Session


Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest inflammasome therapeutic development and research advancements

To submit a poster, or to find out more, contact:

Analyzing the Role of Inflammasomes in Human Disease to Navigate Translational Implications & Optimize Disease Selection

3:00 pm Stimulating Inflammasomes to Promote Memory T-Cell Activation

  • Jonathan Kagan Marian R. Neutra, PhD Professor of Pediatrics, Harvard University


  • Exploring the Connections Between Inflammasome Activation, Inflammatory Cell Death, & Disease
  • How, when, where, and why inflammasomes are expressed to illuminate the geographical location and pattern of activation in the body to explain the connection with disease

3:30 pm Activation of the NLRP1 Inflammasome


  • Discuss how TRX1 and DPP9 restrain inflammasome activation to understand the upstream regulators of inflammasomes
  • Discuss how certain molecule activate NLRP1 to illuminate NLRP1 as a druggable target

4:00 pm Chair’s Closing Remarks

4:15 pm Drinks Reception hosted by Ventus Therapeutics